Safety of influenza immunization during pregnancy for the fetus and the neonate.
Since the 1960s, pregnant women in the United States have been recommended to receive influenza vaccine. A maternal concern about the possibility of adverse fetal and neonatal outcomes after the vaccination of pregnant women has been cited as a reason for low maternal influenza vaccination coverage. Recent research has identified benefits to the fetus and neonate after maternal influenza vaccination that have prompted efforts to increase coverage in pregnant women. There is a long history of research findings that highlight the safety of vaccinating pregnant women. This review summarizes nearly 40 years of research on influenza vaccination of pregnant women and the lack of association with adverse fetal or neonatal outcomes. Future research should focus on vaccinations that are given in the first trimester of pregnancy and on product-specific analyses to account for differences in manufacturing processes.
Center for Health Research-Southeast, Kaiser Permanente, Atlanta, GA, USA.
Robert A
RA
Bednarczyk
Dzifa
D
Adjaye-Gbewonyo
Saad B
SB
Omer
D005260:Female; D005333:Fetus; D014943:Global Health; D006801:Humans; D007231:Infant, Newborn; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control*; D058873:Pandemics; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology / Q000517:prevention & control*; D011256:Pregnancy Outcome; D011295:Prenatal Care; D011356:Product Labeling; D011358:Product Surveillance, Postmarketing; D014481:United States / Q000453:epidemiology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects
D007252:Influenza Vaccines; D015164:Vaccines, Inactivated